Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hyaluronic acid derived maytansine prodrug, preparation method thereof and application of maytansine prodrug in preparation of tumor target treatment medicines

A technology of hyaluronic acid and maytansine, applied in anti-tumor drugs, drug combinations, pharmaceutical formulations, etc., can solve problems such as damage and interstitial lung disease, toxic and side effects, tissue damage, etc., and achieve preservation of anti-tumor activity, Good biological activity and the effect of maintaining medicinal properties

Active Publication Date: 2016-11-23
SUZHOU UNIV
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are obvious deficiencies in these treatment methods: during the treatment process, it will cause irreversible damage to the normal tissues of the body, produce serious toxic and side effects, and bring great pain to patients.
Trastuzumab-maytansine antibody conjugate (T-DM1) has been approved by the FDA for the treatment of advanced HER2-positive breast cancer in 2013, but in addition to production and cost issues, T-DM1 may also cause some Adverse effects such as nausea, musculoskeletal pain, hepatotoxicity, cardiac damage, and interstitial lung disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hyaluronic acid derived maytansine prodrug, preparation method thereof and application of maytansine prodrug in preparation of tumor target treatment medicines
  • Hyaluronic acid derived maytansine prodrug, preparation method thereof and application of maytansine prodrug in preparation of tumor target treatment medicines
  • Hyaluronic acid derived maytansine prodrug, preparation method thereof and application of maytansine prodrug in preparation of tumor target treatment medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 Synthesis of hyaluronic acid derivatized maytansine prodrug (HA-SS-DM1) ( M nHA =35 kDa, DM1% =20 wt.%)

[0038] First, aminodithiopyridine hydrochloride (PDA·HCl) (34.7 mg, 0.156 mmol) was added to hyaluronic acid (HA) (400 mg, 1.04 mmol carboxyl) aqueous solution (20 mL) at room temperature and the whole solution was The pH was adjusted to 6.5, and 4-(4,6-dimethoxytriazin-2-yl)-4-methylmorpholine hydrochloride (DMTMM) (57.51 mg, 0.208mmol) was added thereto at 35 After stirring and reacting at ℃ for 24 hours, it was dialyzed and freeze-dried to obtain hyaluronic acid-dithiopyridine (HA-SS-Py). The product yield was 85%. NMR results showed that its structure was hyaluronic acid-dithiopyridine (HA-SS-Py), and the degree of substitution (DS) of the dithiopyridine functional group (-SS-Py) was 6%. NMR see image 3 , 1 H NMR (D 2 O): Hyaluronic acid (HA): δ (ppm) 1.86-2.01, 3.28-4.02, and 4.21-4.75; Dithiopyridine functional group (-SS-Py): δ (ppm) 2.90 (...

Embodiment 2

[0040] Example 2 Synthesis of hyaluronic acid derivatized maytansine prodrug (HA-SS-DM1) ( M nHA =35 kDa, DM1%=26 wt.%)

[0041] First, aminodithiopyridine hydrochloride (PDA•HCl) (53 mg, 0.24 mmol) was added to hyaluronic acid (HA) (400 mg, 1.04 mmol carboxyl) aqueous solution (20 mL) at room temperature and the whole solution The pH was adjusted to 6.5, and 4-(4,6-dimethoxytriazin-2-yl)-4-methylmorpholine hydrochloride (DMTMM) (86.3 mg, 0.316 mmol) was added thereto at 35 After stirring and reacting at ℃ for 24 hours, it was dialyzed and freeze-dried to obtain hyaluronic acid-dithiopyridine (HA-SS-Py). The product yield was 85%. NMR results showed that its structure was hyaluronic acid-dithiopyridine (HA-SS-Py), and the degree of substitution (DS) of the dithiopyridine functional group (-SS-Py) was 8.5%.

[0042] Under nitrogen protection, HA-SS-Py (100 mg, 40.6 micromole dithiopyridine functional group) dissolved in 8 mL of secondary water was sequentially added to a 1...

Embodiment 3

[0043] Example 3 Synthesis of hyaluronic acid derivatized maytansine prodrug (HA-SS-DM1) ( M nHA =35 kDa, DM1% =30 wt.%)

[0044] First, under nitrogen protection, add aminodithiopyridine hydrochloride (PDA•HCl) (70 mg, 0.312 mmol) to hyaluronic acid (HA) (400 mg, 1.04 mmol carboxyl) aqueous solution (20 mL) The pH of the solution was adjusted to 6.5, and then 4-(4,6-dimethoxytriazin-2-yl)-4-methylmorpholine hydrochloride (DMTMM) (115.01 mg, 0.416 mmol) was added thereto, After stirring and reacting at 35°C for 24 hours, it was dialyzed and freeze-dried to obtain hyaluronic acid-dithiopyridine (HA-SS-Py). The product yield was 85%. NMR results showed that its structure was hyaluronic acid-dithiopyridine (HA-SS-Py), and the degree of substitution (DS) of the dithiopyridine functional group (-SS-Py) was 11%.

[0045] Under nitrogen protection, add HA-SS-Py (100 mg, 54.2 micromole dithiopyridine functional group) dissolved in 8 mL of secondary water into a 100 mL three-necke...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a hyaluronic acid derived maytansine prodrug, a preparation method thereof and application of maytansine prodrug in preparation of tumor target treatment medicines. The maytansine prodrug comprises a hyaluronic acid main chain and a maytansine side chain, wherein maytansine and hyaluronic acid are connected by a disulfide bond, and the hyaluronic acid has a molecular weight of 7-500kDA; and the maytansine content in the hyaluronic acid derived maytansine prodrug is 10-50 percent. The hyaluronic acid derived maytansine prodrug is amphipathic, and can be self-assembled in an aqueous solution to form a nano-drug, the outer hydrophilic layer is formed by hyaluronic acid, and the inner hydrophobic layer is formed by the hydrophobic drug maytansine, so that the maximum tolerated dose of an anti-cancer drug can be improved to a great extent. Furthermore, the hyaluronic acid derived maytansine prodrug has a positive target capability without extra modifying target molecules, has a high enrichment ratio on a tumor part, has high cytotoxicity to tumor cells and canwell inhibit tumor growth in the in-vivo treatment process for a tumor-bearing naked mouse.

Description

technical field [0001] The invention belongs to the field of medical materials, and relates to a polymer prodrug of an anticancer drug and its application; in particular, it relates to a hyaluronic acid derivatized maytansinoid prodrug, its preparation method and its use in the preparation of tumor targeting therapy drugs Applications. Background technique [0002] Malignant cancer has become a major killer threatening human health, and its morbidity and mortality are increasing year by year. Current tumor treatment methods mainly include surgical resection, radiation therapy and chemotherapy. There are obvious deficiencies in these treatment methods: the treatment process will cause irreversible damage to the normal tissue of the body, produce serious toxic and side effects, and bring great pain to the patient. In the past few decades, polymer prodrugs have been developed from being proposed to a nano-drug that is widely recognized by scientists as an effective drug deliv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/48A61K31/537A61K9/19A61P35/00C08B37/08
CPCA61K9/19A61K31/537C08B37/0072
Inventor 钟志远程茹钟平
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com